Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | SIGMAR1 | Q99720 | 12/20 | 0.56 |
| ▸ | HTR1A | P08908 | 4/20 | 0.53 |
| ▸ | HTR2C | P28335 | 3/20 | 0.53 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.49 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.49 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.49 |
| ▸ | HRH1 | P35367 | 1/20 | 0.49 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.48 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.48 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.48 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9685737 | 0.87 | SIGMAR1 (0.64) | SIGMAR1HTR1AHTR2CADRA2AADRA2B | |
| SCHEMBL7765471 | 0.85 | SIGMAR1 (0.54) | MAPTSIGMAR1HTR1AHTR2CADRA2A | |
| SCHEMBL9027509 | 0.85 | SIGMAR1 (0.54) | MAPTSIGMAR1HTR1AHTR2CADRA2A | |
| SCHEMBL7766393 | 0.85 | SIGMAR1 (0.56) | MAPTSIGMAR1HTR1AHTR2CADRA2A | |
| SCHEMBL9685601 | 0.84 | SIGMAR1 (0.60) | SIGMAR1HTR1AHTR2CADRA2AADRA2B | |
| SCHEMBL9484568 | 0.83 | SIGMAR1 (0.62) | SIGMAR1HTR1AHTR2CADRA2AADRA2B | |
| SCHEMBL7761420 | 0.82 | SIGMAR1 (0.59) | SIGMAR1HTR1AHTR2CADRA2AADRA2B | |
| SCHEMBL8114236 | 0.82 | SIGMAR1 (0.59) | SIGMAR1HTR1AHTR2CADRA2AADRA2B | |
| Hydrochloric Acid SCHEMBL8871795 | 0.81 | SIGMAR1 (0.57) | SIGMAR1HTR1AHTR2CADRA2AADRA2B | |
| SCHEMBL9686129 | 0.81 | SIGMAR1 (0.63) | MAPTSIGMAR1HTR1AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165324-A1 | THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE | AGIOS PHARMACEUTICALS, INC. | 2012-06-28 | — | — | US | disclosed |
| US-20100331307-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | AGIOS PHARMACEUTICALS, INC. | 2010-12-30 | — | — | US | disclosed |
| US-5084469-A | Analgesics | ADIR ET COMPAGNIE (FR) | 1992-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331307-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | PDK1, PDK2, PDK3 | MAPT 2867/4885SIGMAR1 3936/4885HTR1A 4695/4885 |
| US-20120165324-A1 | THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE | PDK2, PDK1, PDK3 | MAPT 3834/4885SIGMAR1 3433/4885HTR1A 4514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.